Home | Welcome to Contract Pharma   
Last Updated Saturday, May 30 2015


Financial Report: Amgen

Published August 7, 2014

2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $1.5 billion (+26%)

YTD Revenues: $9.7 billion (+9%)

YTD Earnings: $2.6 billion (-35%)

Comments: Enbrel sales increased 7% to $1.2 billion in the quarter. Kyprolis sales were $78 million (acquired from Onyx Pharmaceuticals acquisision in 4Q13). Prolia sales increased 40% to $264 million. XGEVA sales increased 20% to $299 million, despite generic competition. Combined Neulasta (pegfilgrastim) and NEUPOGEN (filgrastim) sales declined 1% to $1.4 billion in the quarter. R&D expenses in the quarter were up 4% to $979 million.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On